AEM-28 / Capstone - LARVOL DELTA

Characterization of nanodisc-forming peptides for membrane protein studies. (PubMed, J Colloid Interface Sci) - "Our experimental results suggest that AEM28 nanodiscs are suitable for studying membrane proteins with a net positive charge, whereas 2F-based nanodiscs are compatible with any membrane proteins and their complexes irrespective of their charge. Furthermore, both peptides solubilized E. coli cell membranes, indicating their use in membrane protein isolation and other applications related to membrane solubilization."

Journal • Oncology • APOE

Bovine HDL and Dual Domain HDL-Mimetic Peptides Inhibit Tumor Development in Mice. (PubMed, J Cancer Res Ther Oncol) - "We examined whether bovine HDL (bHDL) and three dual-domain peptides, namely AEM-28 and its analog AEM-28-2, and HM-10/10, affect tumor growth and development in mouse models of ovarian and colon cancer...Plasma levels of lysophosphatidic acid (LPA) are significantly reduced in mice that received bHDL and the dual-domain peptides, suggesting that reduction by effecting accumulation and/or synthesis of pro-inflammatory lipids may be one of the mechanisms for the inhibition of tumor development by bHDL and the dual-domain peptides. Our studies suggest that therapeutics based on apolipoproteins present in HDL may be novel agents for the treatment of epithelial adenocarcinomas of the ovary and colon."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Thoracic Cancer

Capstone therapeutics announces phase 1b/2a study results for AEM-28 showing safety and biomarker efficacy signals (GlobeNewswire) - P1/2, N=51; NCT02100839; Sponsor:LipimetiX Development, LLC; "Capstone Therapeutics..and...LipimetiX Development...announced today the completion of and results for its investigational AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in cholesterol and lipid reduction. The top-line data from the Phase 1a (reported on September 2, 2014) and Phase 1b/2a blended protocol has been analyzed...p < 0.05 favoring AEM-28 vs. placebo within the first 12 hours post infusion at the highest dose tested of 3.54mg/kg in VLDL, equating to a maximum 76% drop in VLDL vs. baseline and a 56% net maximum reduction of VLDL vs. placebo..."

P1/2 data • Trial completion • Atherosclerosis • Dyslipidemia

Safety study of AEM-28 to treat refractory hypercholesterolemia (clinicaltrials.gov) - P1/2, N=51; Sponsor: LipimetiX; Recruiting; New P1/2 trial; Phase shift: Preclinical -> P2.

New P1/2 trial • Phase shift